2005

Fat Binding Capacity of Liposinol™ Patented Fibre Complex in American Breakfast

The TNO-report is based on a gastro-intestinal model simulating very closely the dynamic processes in the gastro-intestinal tract such as the pH curves and concentrations of (pro-)enzymes in the stomach and small intestine, concentration of bile salts in the different parts of the gut, and the kinetics of passage of chime through the stomach and intestine. This model system is USFDA validated gastrointestinal model and has been accepted by several local authorities¹ .

The aim of the study was to determine the fat binding behaviour of the Liposinol™ patented fibre complex, added to an American breakfast, during passage through the gastric and small intestinal model.

Methods:

The experiments were performed under the average conditions of the gastrointestinal tract as described for healthy young adults after the intake of a breakfast. A specific absorption system is used to remove products of lipid digestion and lipophilic compounds that are incorporated in mixed micelles. The removed material was collected to determine the bio accessible fraction. The tests were performed in duplicate, for 4 hours. The efficacy of the Liposinol™ patented fibre complex to bind fat was tested by measuring the bio-accessible lipid fraction at the dosage of 2g of the Liposinol™ patented fibre complex preliminary mixed with sunflower oil (3g), and added to an American breakfast.

Conclusion:

This study confirmed the fat binding capacity of the Liposinol™ patented fibre complex when it is added to a complex food formula, the FDA American breakfast.

Results:

The results confirmed the properties of the patented fibre complex of Liposinol™, so confirming previous results obtained with the same TNO model. The patented fibre complex of Liposinol™ absorbs about 23% of total fatty acids compared to control with American breakfast. Figure 1: Dietary fat content excreted